K
Klaus Krueger
Researcher at Praxis
Publications - 33
Citations - 882
Klaus Krueger is an academic researcher from Praxis. The author has contributed to research in topics: Rheumatoid arthritis & Internal medicine. The author has an hindex of 9, co-authored 28 publications receiving 776 citations.
Papers
More filters
Proceedings ArticleDOI
Fri0103 benefit study: a pan-european observational study to evaluate real-world effectiveness of sb4 following transition from originator etanercept (etn) in patients with rheumatoid arthritis (ra) or axial spondyloarthritis (axspa)
Klaus Krueger,Carlo Selmi,Alain Cantagrel,Abad Hernández,Ulrich Freudensprung,Mourad Farouk Rezk,Janet Addison +6 more
TL;DR: Patients had RA or axSpA and had initiated SB4 in routine clinical practice following a minimum of 6 months treatment with a stable dose of originator ETN, at clinics in France, Germany, Italy, and Spain and there was no clinically significant difference in disease score from baseline to 6 months post-transition.
Proceedings ArticleDOI
OP0249 Multi-biomarker disease activity and autoantibody status lead to cost effective tapering algorithms in rheumatoid arthritis patients in sustained remission
Melanie Hagen,Matthias Englbrecht,Judith Haschka,Michaela Reiser,A. Kleyer,Axel J. Hueber,Bernhard Manger,C Figuereido,J Fogagnolo Cobra,H-P Tony,Stephanie Finzel,Stefan Kleinert,Jörg Wendler,F. Schuch,Monika Ronneberger,Martin Feuchtenberger,Martin Fleck,K. Manger,Wolfgang Ochs,M. Schmitt-Haendle,H.-M. Lorenz,H. Nuesslein,R. Alten,Jörg Henes,Klaus Krueger,Georg Schett,Jürgen Rech +26 more
TL;DR: Combining MBDA score and ACPA status allows risk stratification for successful DMARD tapering and cost-effective use of biologic DMARD.
Journal ArticleDOI
AB0189 Anti-Modified Protein Antibody Response Pattern Influences The Risk for Disease Relapse in Rheumatoid Arthritis Patients Tapering Disease Modifying Anti-Rheumatic Drugs
Cmbf Figueiredo,Holger Bang,Jayme Fogagnolo Cobra,Matthias Englbrecht,Axel J. Hueber,Judith Haschka,Bernhard Manger,A. Kleyer,Michaela Reiser,Stephanie Finzel,H-P Tony,Stefan Kleinert,Jörg Wendler,F. Schuch,Monika Ronneberger,Martin Feuchtenberger,Martin Fleck,K. Manger,Wolfgang Ochs,M. Schmitt-Haendle,H.-M. Lorenz,H. Nuesslein,Rieke Alten,Jörg Henes,Klaus Krueger,Jürgen Rech,Georg Schett +26 more
TL;DR: The data suggest that the pattern of anti-modified protein antibody response determines the risk of disease relapse in RA patients tapering DMARD therapy.
Journal ArticleDOI
Correspondence to 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'.
Hendrik Schulze-Koops,Alla Skapenko,Andreas Krause,Klaus Krueger,Hanns Martin Lorenz,Philipp Sewerin,Christof Specker,Ulf G. Wagner,A. Voormann,Ulf Mueller-Ladner,Reinhard E. Voll +10 more
TL;DR: Comparisons of patients with IRDs and the non-rheumatic population have shown that patients withIRDs do not actually have a different risk of infection than the general population, and these data are reassuring, as they underline once again that well-controlled IRDs per se do not pose a risk of contracting SARS-CoV-2 nor do ongoing immunomodulating therapies pose a threat for Patients with IRD.
Journal ArticleDOI
THU0130 Adherence to DMARDS in Patients with Rheumatoid Arthritis - A Multicenter Outpatient Study
TL;DR: Patient-reported adherence to MTX as well as other DMARD therapy is high in Germany according to SSQ, and considerable difference exists, however, between high adherence directly reported by patients (SSQ) and low adherence assessed by CQR.